Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 23, 2010

AstraZeneca and Abbott Pull NDA for Lipidemia Drug

  • AstraZeneca and Abbott are ceasing development of the FDA-filed mixed lipidemia therapy candidate Certriad™. The drug is a combination of AstraZeneca’s Crestor (rosuvastatin calcium) and Abbott’s Trilipix (fenofibric acid).

    The firms had filed an NDA with FDA for Certriad in June 2009. In March received a complete response letter (CRL) from the agency.

    They say the joint decision to drop the drug follows a careful review of the CRL and the resulting regulatory delay, which led them to conclude that development of Certriad is no longer commercially viable.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Pharmacists and Prescription Drug Misuse Programs

Do you agree that pharmacists should make a greater effort to become more involved with prescription drug-monitoring programs?

More »